Teva loses plea against GSK’s $235m ‘skinny label’ win

16-05-2023

Sarah Speight

Teva loses plea against GSK’s $235m ‘skinny label’ win

JHVEphoto / Shutterstock.com

The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.


Teva, GSK, SCOTUS, US Supreme Court, US Court of Appeals, Federal Circuit, skinny labelling, carving out, carvedilol, Coreg, pharmaceuticals

LSIPR